findmyKOL

Paul Gerczuk, MD

Basic profile

AdventHealth Tampa

ORCIDNone on fileNPI
RegionTampa, FL · SoutheastSpecialtyClinical Cardiac ElectrophysiologyFocusCardiology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Paul Gerczuk is a Cardiology physician affiliated with AdventHealth Tampa. OpenAlex indexes 17 publications with 408 citations (h-index 9).

Overview

Scholarship

indexed output and impact (OpenAlex)
17publications

Distinct works indexed by OpenAlex.

408citations

Total citations across indexed works.

9h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    76.4%
    Beta blocker19.1%
    Metoprolol Succinate34%Carvedilol27%Bisoprolol Fumarate19%Metoprolol Tartrate9%Sotalol8%Atenolol2%Propranolol Hcl1%
    Part D<11 patients
    Antiarrhythmic16%
    Amiodarone Hcl41%Flecainide Acetate32%Dofetilide16%Multaq6%Propafenone Hcl3%Propafenone Hcl Er3%
    Part D<11 patients

    + 15 more classes in this area

  • Blood & clotting

    21.3%
    Factor Xa inhibitor18.5%
    Eliquis73%Xarelto27%
    Part D165 patients
    P2Y12 inhibitor2.1%
    Clopidogrel100%
    Part D40 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    1.6%
    Potassium supplement0.8%
    Potassium Chloride100%
    Part D19 patients
    Proton pump inhibitor0.4%
    Pantoprazole Sodium100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)26.1% facility · 73.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”